Table 2.

Validation analysis of potentially novel DDIs, manual chart review results

Object Drug	Potential Precipitant Drug	% TP Drug-ADR(TP/number of patients reviewed)	Comments
simvastatin	HCTZ	100 (10/10)	NA
simvastatin	triamterene	100 (10/10)	All DDIWAS-derived (+simvastatin-ADR, +triamterene-ADR) patients were exposed to triamterene via a HCTZ/triamterene combination drug.
amlodipine	ezetimibe	90 (9/10)	Majority (8/10) of DDIWAS-derived (+amlodipine-ADR, +ezetimibe-ADR) patients also had a statin drug on their allergy lists. The single false-positive DDIWAS-derived (+amlodipine-ADR, +ezetimibe-ADR) patient had neither the object nor potential precipitant drug on their allergy list.
amlodipine	levothyroxine	40 (2/5)	Reviewed all 5 available DDIWAS-derived (+amlodipine-ADR, +levothyroxine-ADR) patients. Two false-positive DDIWAS-derived (+amlodipine-ADR, +levothyroxine-ADR) patients had neither the object nor potential precipitant drug on their allergy lists. One false-positive DDIWAS-derived (+amlodipine-ADR, +levothyroxine-ADR) patient did not have the potential precipitant drug on their allergy list.
amlodipine	valacyclovir	80 (4/5)	Reviewed all 5 available DDIWAS-derived (+amlodipine-ADR, +valacyclovir-ADR) patients. The single false-positive DDIWAS-derived (+amlodipine-ADR, +valacyclovir-ADR) patient had neither amlodipine nor valacyclovir on their allergy list.
amlodipine	omeprazole	100 (10/10)	NA

True-positive patients were those for whom healthcare providers intentionally added both the object and potential precipitant drugs to their allergy lists.

Abbreviations: ADR, adverse drug reaction; DDIWAS, Drug-Drug-Interaction Wide Association Study; HCTZ, hydrochlorothiazide; TP, true-positive.